Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations

European Journal of Cancer Part A

Volumn 32, Issue 9, 1996, Pages 1544-1550

  Boos, J ^a   Werber, G ^a   Ahlke, E ^a   Schulze Westhoff, P ^a   Nowak Gottl U ^a   Wurthwein G ^a   Verspohl, E J ^a   Ritter, J ^a   Jurgens H ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Asparaginase; Asparagine; Child; Drug monitoring; Leukaemia; Pharmacokinetics

Indexed keywords

ASPARAGINASE; ASPARAGINASE MEDAC; ASPARAGINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; PREDNISONE; TIOGUANINE; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG MONITORING; ENZYME ACTIVITY; FEMALE; HUMAN; INFANT; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030218821     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00131-1     Document Type: Article

References (32)

1. 1. Sallan SE, Hitchcock BS, Gelber R, Cassady JR, Frei E, Nathan DG. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983, 43, 5601-5607.
2. 2. Broome JD. L-Asparaginase: discovery and development as a tumor-inhibitory agent. Cancer Treat Rep 1981, 65(Suppl 4), 111-114.
3. 3. Wriston JC Jr, Yellin TO. L-Asparaginase: review. Adv Enzymol Relat Areas Mol Biol 1973, 39, 185-248.
4. 4. Chabner BA. Enzyme therapy: L-asparaginase. In Chabner BA, Collins JM, eds. Cancer Chemotherapy: Principles and Practice. Philadelphia, J.B. Lippincott Company, 1990, 397-407.
5. 5. Capizzi RL, Holcenberg JS. Asparaginase. In Holland JF, Frei III E, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer Medicine. Philadelphia and London, Lea & Febiger, 1993, 796-803.
6. 6. Miller HK, Salser JS, Balis ME. Amino acid levels following L-asparaginase amidohydrolase (EC.3.5.1.1) therapy. Cancer Res 1969, 29, 183-187.
7. 7. Nakamura N, Morikawa Y, Tanaky M. L-Asparaginase from Escherichia coli. Part II. Substrate Specifity Studies. Agr Biol Chem 1971, 35, 743-751.
8. 8. Ollenschläger G, Roth E, Linkesch W, Jansen S, Simmel A, Mödder B. Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. Eur J Clin Invest 1988, 18, 512-516.
9. 9. Villa P, Corada M, Bartosek I. L-Asparaginase effects on inhibition of protein synthesis and lowering of the glutamate content in cultured rat hepatocytes. Toxicol Lett 1986, 32, 235-241.
10. 10. Andrew M, Brooker L, Mitchell L. Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukemia. Blood Coagulation and Fibrinolysis 1994, 5, 24-36.
11. 11. Sutor AH, Niemeyer C, Sauter S, et al. Gerinnungsveränderungen bei Behandlung mit den Protokollen ALL-BFM-90 und NHL-BFM-90. Klin Pädiatr 1992, 204, 264-273.
12. 12. Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L-asparaginase-induced antithrombin III deficiency. Blood 1994, 83, 386-391.
13. 13. Nowak-Göttl U, Wolff JEA, Kuhn N, et al. Enhanced thrombin generation, P-von Willebrand Factor, P-Fibrin D-Dimer and P-Plasminogen Activator Inhibitor 1: predictive for venous thrombosis in asparaginase-treated children. Fibronolysis 1994, 8(Suppl. 2), 63-65.
14. 14. Mitchell L, Sutor A, Andrew M. Haemostasis in childhood lymphoblastic leukemia: coagulopathy induced by disease and treatment. Sem Thromb Hemost 1995, 21, 390-401.
15. 15. Mashburn LT, Wriston JC Jr. Tumor inhibition effect of L-asparaginase from Escherichia coli. Arch Biochem Biophys 1964, 105, 450-452.
16. 16. Wade HE, Elsworth R, Herbert D, Keppie J, Sargeant K. A new L-asparaginase with antitumour activity? Lancet 1968, 2, 776-777.
17. 17. Koerholz D, Brueck M, Nuernberger W, Juergens H, Goebel U, Wahn V. Chemical and immunological characteristics of four different L-asparaginase preparations. Eur J Haematol 1989, 42, 417-424.
18. 18. Eden OB, Shaw MP, Lilleyman JS, Richards S. Non-randomized study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukemia. Med Pediat Oncol 1990, 18, 497-502.
19. 19. Ohnuma T, Holland JF, Meyer P. Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli. Cancer 1972, 30, 376-381.
20. 20. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993, 11, 1780-1786.
21. 21. Handschumacher RE, Bates CJ, Chang PK, Andrews AT, Fischer GA. 5-Diazo-4-Oxo-L-norvalin: reactive asparagine analog with biological specificity. Science 1968, 161, 62-63.
22. 22. Asselin BL, Lorenson MY, Whitin JC, et al. Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor. Cancer Res 1991, 51, 6568-6573.
23. 23. Werber G, Ahlke E, Nowak-Göttl U, Jürgens H, Verspohl EJ, Boos J. Asparaginase activities in vitro are highly sensitive to different buffer conditions. Haematology and Blood Transfusion 1996, 38 (in press).
24. 24. Lenda K, Svenneby G. Rapid high-performance liquid chromatographic determination of amino acids in synaptosomal extracts. J Chromatogr 1980, 198, 516-519.
25. 25. Gentili D, Zucchetti M, Conter V, Masera G, D'Incalci M. Determination of L-asparagine in biological samples in the presence of L-asparaginase. J Chromatogr 1994, B657, 47-52.
26. 26. Schwartz MK, Lash ED, Oettgen HF. L-Asparaginase activity in plasma and other biological fluids. Cancer 1970, 25, 244-252.
27. 27. Nowak-Göttl U, Boos J, Wolff JEA, et al. Influence of two different E. coli asparaginase preparations on coagulation and fibrinolysis: a randomized trial. Fibrinolysis 1994, 8(Suppl. 2), 66-68.
28. 28. Glutamate: Transmitter and Toxin. International Workshop, Wiesbaden, November 1992. Kempski O, ed. München, Bern, Wien, New York, W. Zuckschwerdt Verlag, 1993.
29. 29. Dibenedetto SP, Di Cataldo A, Ragusa R, Meli C, Lo Nigro L. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia. J Clin Oncol 1995, 13, 339-344.
30. 30. Riccardi R, Holcenberg JS, Glaubiger DL, Wood JH, Poplack DG. L-Asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981, 41, 4554-4558.
31. 31. Boos J, Nowak-Göttl U, Jürgens H, Fleichhack G, Bode U. Loss of activity of Erwinia asparaginase on repeat applications. J Clin Oncol 1995, 13, 2474-2475.
32. 32. Nesbit ME, Ertel I, Hammond GD. L-Asparaginase as a single agent in acute lymphocytic leukemia: survey of studies from childrens cancer study group. Cancer Treat Rep 1981, 65(Suppl. 4), 101-107.